- Pfizer joins the more than 50 other partners committed to accelerating the development of new treatments and enable precision medicine in blood cancer
- In total, more than 90 multi-disciplinary contributors including academic institutions, hospitals, national clinical disease networks, patient groups and pharmaceutical companies, as well as regulatory agencies, experts in economics and ethics, and information and technology (ICT) specialists form the HARMONY Alliance
HARMONY announced today that Pfizer has become a partner in the HARMONY Alliance, which is orchestrating the consolidation of data from more than 90 contributors into one common platform – the HARMONY Big Data Platform – with the goal of transforming the care and treatment of people with blood cancers. Hematological malignancies are a leading contributor to cancer incidence and mortality across Europe with a large economic burden and a significant impact on society. In addition, healthcare practice varies across countries and fragmentation and a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and decision-makers alike.
The HARMONY project aims to use ‘big data’ to deliver information that will help to improve the care of patients with these diseases by gathering, integrating and analyzing anonymous patient data from a number of high-quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognized by all key stakeholders. The project’s data sharing platform aims to facilitate and improve decision making for policy makers and clinicians alike, to help them to give the right treatment to the right patient at the right time.
“We are very excited to have Pfizer join the HARMONY Alliance to contribute their extensive expertise in blood cancers to the growing wealth of data that we are collecting and mining,” says Jesús María Hernández Rivas from the Institute for Biomedical Research of Salamanca (IBSAL) and HARMONY Coordinator.
“We are proud to join and contribute to this project, as it shares in our goal of improving care and outcomes for patients with hematologic malignancies,” said Farzad Ali, Global Team Leader, Patient Health Impact, Hematology, Pfizer.
HARMONY comprises partners, associated members and patient organizations from a broad spectrum of disciplines; these include academic institutions, national clinical disease networks, patient advocacy groups, hospitals, regulatory agencies, health technology assessment bodies, technology specialists and pharmaceutical companies.
HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Read more >
Learn more about this in this link: https://www.harmony-alliance.eu/en/news/wp7/press-release-harmony-welcomes-pfizer-as-new-partner